Racial Disparity in Breast Cancer Outcomes Among Underinsured (06/30/2010)
Underinsured African-Americans have worse breast cancer survival outcomes than their underinsured White counterparts, according to the results of a study published early online in the Journal of the National Caner Institute.

Racial Disparity in Breast Cancer Outcomes Among Underinsured (06/30/2010)
Underinsured African-Americans have worse breast cancer survival outcomes than their underinsured White counterparts, according to the results of a study published early online in the Journal of the National Caner Institute.

Tykerb plus Taxol Is Active in Inflammatory Breast Cancer (06/17/2010)
Tykerb® (lapatinib) plus Taxol® (paclitaxel) appears to provide benefit in the initial treatment of inflammatory breast cancer, according to results published in the Journal of Clinical Oncology.

FDA Advisory Committee Recommends that Avastin No Longer Be Approved for Breast Cancer (07/29/2010)
The Oncology Drugs Advisory Committee (ODAC) of the United States Food and Drug Administration (FDA) has voted 12 to one that Avastin® (bevacizumab) in combination with paclitaxel should no longer be approved for initial therapy for metastatic HER2-negative breast cancer.

Olaparib Active Against Advanced Ovarian Cancer and Breast Cancer with BRCA Mutations (07/20/2010)
Previously treated advanced breast and ovarian cancer patients with BRCA1 or BRCA2 gene mutation may benefit from treatment with the oral investigational drug olaparib.

Racial Disparity in Breast Cancer Outcomes Among Underinsured (06/30/2010)
Underinsured African-Americans have worse breast cancer survival outcomes than their underinsured White counterparts, according to the results of a study published early online in the Journal of the National Caner Institute.

Metastases from Breast Cancer May Differ from Primary Tumor (06/09/2010)
It appears that in metastatic breast cancer, the biologic characteristics of liver metastases sometimes differ from those of the primary tumor. This finding may affect treatment choices for metastases. Results of this retrospective study were presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Olaparib Active Against Advanced Ovarian Cancer and Breast Cancer with BRCA Mutations (07/20/2010)
Previously treated advanced breast and ovarian cancer patients with BRCA1 or BRCA2 gene mutation may benefit from treatment with the oral investigational drug olaparib.

Racial Disparity in Breast Cancer Outcomes Among Underinsured (06/30/2010)
Underinsured African-Americans have worse breast cancer survival outcomes than their underinsured White counterparts, according to the results of a study published early online in the Journal of the National Caner Institute.

Eribulin Improves Survival with Metastatic Breast Cancer (06/08/2010)
Among women with previously treated, locally recurrent or metastatic breast cancer, treatment with the investigational chemotherapy drug eribulin mesylate improved overall survival by about 2.5 months. The results of this Phase III clinical trial were presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Optimal Outcomes with Vascular Endothelial Growth Factor (VEGF) (05/28/2010)
An expert panel provided consensus recommendations for appropriate prevention, surveillance and treatment of hypertension (high blood pressure) in patients treated with vascular endothelial growth factor (VEGF) signaling pathway inhibitors. These recommendations were recently published in the Journal of the National Cancer Institute.

Alcohol Linked with Lobular Breast Cancer (09/03/2010)
Although alcohol is a well-established risk factor for breast cancer, it may be more strongly linked with lobular breast cancer than with ductal breast cancer. These results were published in the Journal of the National Cancer Institute.

Additional Research on Menopausal Hormone Therapy and Breast Cancer (08/24/2010)
A recent study of menopausal hormone therapy and risk of breast cancer reported that risk may vary by body weight and the type of hormone therapy. These results were published in Cancer Epidemiology, Biomarkers, & Prevention.

Mediterranean Diet May Lower Breast Cancer Risk (08/16/2010)
Postmenopausal women who consume a traditional Mediterranean diet may have a lower risk for breast cancer, according to a study published in the American Journal of Clinical Nutrition.

Breast Density and Hormone Therapy Add to Breast Cancer Risk (08/04/2010)
Postmenopausal women with high breast density are at an increased risk of developing breast cancer, according to the results of a study published in the Journal of Clinical Oncology. This risk increases with the use of hormone therapy.

Making Sense of New Mammography Recommendations (07/20/2010)
The U.S. Preventive Services Tasks Force (USPSTF) has reversed its position on screening mammography for women in their 40s: the group no longer recommends routine screening mammography for average-risk women in this age group. The American Cancer Society, however, has stated that it will continue to recommend annual mammograms starting at the age of 40.

Screening Rates Among Older Americans (07/15/2010)
More older Americans are undergoing screening for colon cancer, but the rates for breast cancer screening remain the same, according to a government report released on July 6, 2010.

Study Evaluates Impact of Lymph Node Removal in Early-stage Breast Cancer (08/13/2010)
Early-stage breast cancer patients without evidence of cancer in their sentinel lymph node who did not have additional lymph nodes removed report fewer side effects to the arm and breast than patients who undergo additional lymph node removal.

Updated Guidelines Address Hormonal Therapy for Breast Cancer (07/21/2010)
Among postmenopausal women with hormone receptor-positive breast cancer, use of an aromatase inhibitor at some point in the course of adjuvant (post-surgery) treatment results in a lower risk of cancer recurrence than use of tamoxifen only.

Many Breast Cancer Patients Taking Adjuvant Hormonal Therapy Stop Treatment Early (07/01/2010)
Less than half of early-stage breast cancer patients with hormone-sensitive disease completed the full dose and schedule of their hormonal therapy treatment. These findings were recently published in the Journal of Clinical Oncology.

Racial Disparity in Breast Cancer Outcomes Among Underinsured (06/30/2010)
Underinsured African-Americans have worse breast cancer survival outcomes than their underinsured White counterparts, according to the results of a study published early online in the Journal of the National Caner Institute.

Gene Mutation Increases Risk of Blood Clots in Breast Cancer Patients Taking Tamoxifen (06/29/2010)
Among women taking tamoxifen for early-stage breast cancer, an inherited gene mutation (Factor V Leiden) may increase the risk of blood clots.

Low Incidence of Heart Complications with Herceptin in Breast Cancer (06/17/2010)
Even with longer-term follow-up, heart problems are not common among breast cancer patients treated with Herceptin® (trastuzumab). These results were published in the Journal of Clinical Oncology.

Study Evaluates Impact of Lymph Node Removal in Early-stage Breast Cancer (08/13/2010)
Early-stage breast cancer patients without evidence of cancer in their sentinel lymph node who did not have additional lymph nodes removed report fewer side effects to the arm and breast than patients who undergo additional lymph node removal.

Many Breast Cancer Patients Taking Adjuvant Hormonal Therapy Stop Treatment Early (07/01/2010)
Less than half of early-stage breast cancer patients with hormone-sensitive disease completed the full dose and schedule of their hormonal therapy treatment. These findings were recently published in the Journal of Clinical Oncology.

Racial Disparity in Breast Cancer Outcomes Among Underinsured (06/30/2010)
Underinsured African-Americans have worse breast cancer survival outcomes than their underinsured White counterparts, according to the results of a study published early online in the Journal of the National Caner Institute.

Gene Mutation Increases Risk of Blood Clots in Breast Cancer Patients Taking Tamoxifen (06/29/2010)
Among women taking tamoxifen for early-stage breast cancer, an inherited gene mutation (Factor V Leiden) may increase the risk of blood clots.

Low Incidence of Heart Complications with Herceptin in Breast Cancer (06/17/2010)
Even with longer-term follow-up, heart problems are not common among breast cancer patients treated with Herceptin® (trastuzumab). These results were published in the Journal of Clinical Oncology.

Single-dose Radiation in Early Breast Cancer (06/14/2010)
A single dose of radiotherapy delivered at the time of surgery may be an effective alternative to external beam radiation delivered over several weeks among selected patients with early breast cancer. Findings of this international Phase III trial were published in The Lancet.